← Back to Search

Controlled Breathing for POTS

N/A
Recruiting
Led By Satish R Raj, MD, MSCI
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18-60 years
Physician diagnosis of Postural Tachycardia Syndrome (POTS)
Must not have
Subjects who require portable oxygen at rest or with exercise
Subjects with chronic heart failure or severe pulmonary disease who are unable to climb one flight of stairs due to shortness of breath
Timeline
Screening 3 weeks
Treatment Varies
Follow Up difference between hr from supine to peak hr during tilt test for each intervention (mean value hr between the 8th and 9th minute of supine; peak parameters, during hutt, mean value during the first min and between the 3rd and 8th min)
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether CO2 can help people with POTS by lowering heart rate and reducing symptoms when upright/standing.

Who is the study for?
This trial is for adults aged 18-60 with a physician's diagnosis of Postural Tachycardia Syndrome (POTS) who can visit the University of Calgary and are non-smokers. Pregnant individuals, those needing portable oxygen, or with severe heart/lung disease, anxiety disorders, or poor past study compliance cannot participate.
What is being tested?
The study tests if controlled breathing using the RespirAct™ system to increase CO2 levels can reduce rapid heartbeat and improve symptoms in POTS patients when standing. The goal is to find the best CO2 level for symptom relief.
What are the potential side effects?
Potential side effects may include discomfort from wearing a mask during the study and possible dizziness or shortness of breath due to changes in CO2 levels while using the RespirAct™ system.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 60 years old.
Select...
I have been diagnosed with POTS by a doctor.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I need portable oxygen for breathing, either at rest or during physical activity.
Select...
I cannot climb stairs without feeling short of breath due to heart or lung problems.
Select...
I have a rapid heartbeat when standing up due to severe dehydration.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~difference between hr from supine to peak hr during tilt test for each intervention (mean value hr between the 8th and 9th minute of supine; peak parameters, during hutt, mean value during the first min and between the 3rd and 8th min)
This trial's timeline: 3 weeks for screening, Varies for treatment, and difference between hr from supine to peak hr during tilt test for each intervention (mean value hr between the 8th and 9th minute of supine; peak parameters, during hutt, mean value during the first min and between the 3rd and 8th min) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Heart Rate (HR) variation
Secondary study objectives
Cerebral blood flow velocity (CBFv) variation
VOSS symptom score

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: All participantsExperimental Treatment1 Intervention
All participants will receive the same interventions

Find a Location

Who is running the clinical trial?

University of CalgaryLead Sponsor
808 Previous Clinical Trials
884,363 Total Patients Enrolled
8 Trials studying Postural Orthostatic Tachycardia Syndrome
637 Patients Enrolled for Postural Orthostatic Tachycardia Syndrome
Satish R Raj, MD, MSCIPrincipal InvestigatorUniversity of Calgary, Cardiac Science
4 Previous Clinical Trials
261 Total Patients Enrolled
2 Trials studying Postural Orthostatic Tachycardia Syndrome
157 Patients Enrolled for Postural Orthostatic Tachycardia Syndrome

Media Library

RespirAct™ system Clinical Trial Eligibility Overview. Trial Name: NCT04271878 — N/A
Postural Orthostatic Tachycardia Syndrome Research Study Groups: All participants
Postural Orthostatic Tachycardia Syndrome Clinical Trial 2023: RespirAct™ system Highlights & Side Effects. Trial Name: NCT04271878 — N/A
RespirAct™ system 2023 Treatment Timeline for Medical Study. Trial Name: NCT04271878 — N/A
~11 spots leftby Dec 2026